ArQule, Inc. (ARQL) is an oncology-focused microcap biotechnology company. A graphical description of its pipeline shows six ongoing clinical trials studying five products. Its shares currently trade for under $2.20, after moving up and then down again in 2014, pursuant to depreciating through the past year and being removed from the NASDAQ Biotechnology Index (IBB) on December 23rd.
ArQule has some cash on hand as well as investments. Though the company has obtained funds through partnerships, and might continue to in the future, it is not financially self-sustaining. Yet, there appear to be multiple ways for the experimental firm to reward investors. One reason is that it has a considerable amount of Net...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: